Atrium's PRKAG2 Gene Silencer Enters Clinic Facing Precedent-Based Efficacy Doubts

FDA Clears Atrium's IND for Corventis Trial in PRKAG2 Syndrome

Atrium Therapeutics has received US Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application to initiate the Corventis Phase I/II clinical trial of ATR 1072. This trial will investigate the drug for Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome, a rare, early-onset cardiomyopathy. The open-label, multi-centre study plans to enroll approximately 37 participants in the US, with the first participant expected by the end of 2026 and initial proof-of-concept data anticipated in the second half of 2027. ATR 1072 is designed to address the root cause of the disease by silencing mutant PRKAG2 messenger RNA.

• The Corventis Phase I/II trial is an open-label, multi-centre study in the US, enrolling approximately 37 participants. Part A will focus on multiple-ascending dose cohorts to assess safety and determine optimal dosing, while Part B will be a single-arm expansion cohort at the selected Phase II dose to evaluate safety and efficacy trends in cardiac function and structure.
• PRKAG2 syndrome is highlighted as a progressive, life-altering, and life-threatening rare genetic cardiomyopathy with no approved therapies targeting its root cause. Atrium Therapeutics aims to deliver potential disease-modifying treatments for patients suffering from this condition, reinforcing the urgency and significance of the IND clearance.
• ATR 1072, Atrium Therapeutics’ lead product candidate, employs small interfering RNA (siRNA) technology. Its mechanism involves silencing mutant PRKAG2 messenger RNA, which is intended to normalize protein kinase activity and reduce the harmful glycogen build-up in the heart that characterizes PRKAG2 syndrome.

Addressing the Profound Unmet Need in PRKAG2 Syndrome

PRKAG2 cardiac syndrome is a progressive and incurable condition that presents significant treatment challenges, largely due to its rarity and the absence of established management guidelines. Current therapeutic strategies are not curative and focus primarily on symptomatic control, leaving a substantial unmet medical need for a patient population that includes young individuals with severe, de novo mutations.

• Absence of Disease-Modifying Therapies: With no cure or approved targeted treatments, clinical management is restricted to symptomatic control. This includes the use of antiarrhythmic drugs, anticoagulation, radiofrequency catheter ablation, and management of comorbidities, which do not address the underlying disease progression.

• High Burden of Cardiac Events: Current approaches are often insufficient to prevent severe outcomes. The disease's progressive nature leads to a high incidence of life-threatening events, with studies showing 11.1% of patients experiencing sudden cardiac death and 33.3% requiring pacemaker implantation.

• Complex Pathophysiology: Developing effective therapies is complicated by the disease's multifaceted pathology. Key mechanisms include excessive glycogen deposition in cardiomyocytes, cardiac hypertrophy, ventricular preexcitation, progressive conduction system disease, and arrhythmias, all contributing to the development of congestive heart failure.

• Intricate Molecular Signaling: The disease involves complex signaling disruptions, including hyperactivity of the Akt/mTOR pathway and inactivation of FoxO transcription factor signaling. While preclinical models targeting these pathways show promise, translating these findings into clinical therapies remains a key challenge.

• Diagnostic Challenges: The clinical presentation of PRKAG2 syndrome, particularly its cardiac features, can closely mimic Pompe disease. This overlap can lead to misdiagnosis, delaying appropriate monitoring and management strategies and, in some reported cases, resulting in the initiation of incorrect treatments like enzyme replacement therapy.

Unpacking the Genetic Roots of PRKAG2 Syndrome

PRKAG2 syndrome is driven by autosomal dominant mutations in the PRKAG2 gene, which encodes the γ2 regulatory subunit of AMP-activated protein kinase (AMPK), a critical cellular energy sensor that modulates glucose uptake and glycolysis. The identified pathogenic variants, such as R302Q, N488I, and H530R, are typically missense mutations located within cystathionine beta-synthase (CBS) domains. These alterations impair the binding of adenosine derivatives like AMP and ATP, disrupting the enzyme's normal allosteric regulation. This leads to inappropriate and constitutive activation of AMPK, particularly in heterotrimeric complexes containing the α2 catalytic subunit. Other mutations, such as G100S in a non-CBS domain, also dysregulate AMPK by attenuating its activity and reducing protein expression, highlighting the complex effects of genetic variants on enzyme function.

The primary downstream effect of this chronic AMPK dysregulation is a profound derangement of cardiac metabolism and structure, classifying the condition as a myocardial metabolic storage disease. Inappropriate AMPK activation drives excessive glucose uptake, resulting in massive glycogen accumulation within cardiomyocytes. This leads to a distinct cellular pathology characterized by myocyte enlargement and pronounced vacuole formation from glycogen-filled granules, distinguishing it from the myofibrillar disarray typical of sarcomeric hypertrophic cardiomyopathy. In addition to the storage phenotype, PRKAG2 mutations facilitate the postnatal development of accessory electrical pathways. Histological evidence from murine models shows myocardial connections forming across the annulus fibrosus of the atrioventricular valves, creating the substrate for ventricular pre-excitation (Wolff-Parkinson-White syndrome).

Beyond glycogen storage, research suggests that PRKAG2 mutations may also activate pro-growth signaling pathways. One proposed mechanism involves increased insulin sensitivity and hyperactivity of the Akt signaling cascade, leading to activation of the mammalian target of rapamycin (mTOR) and contributing to cardiac hypertrophy independent of glycogen accumulation. The development of advanced models, including patient-derived induced pluripotent stem cells (hiPSCs) and transgenic mice, has been crucial for dissecting these pathways. These models, which recapitulate key disease phenotypes like cellular enlargement and electrophysiological defects, have enabled the exploration of novel therapeutic strategies. Promising preclinical results include the alleviation of cellular phenotypes with small molecule AMPK inhibitors and the restoration of heart morphology and function in mouse models using CRISPR-Cas9 genome editing to selectively disrupt the mutant allele.

Shaping the Future Treatment Landscape for PRKAG2 Syndrome

Based on recent cohort studies and case reports, the management of PRKAG2 syndrome predominantly relies on supportive care and device-based interventions rather than novel therapeutics from clinical trials. A 2024 long-term follow-up of a family cohort carrying the p.K290I variant documented interventions including antiarrhythmic drugs, anticoagulation, pacemaker implantation, and radiofrequency catheter ablation, which collectively improved symptoms and survival rates. Device implantation is common; this cohort had eight pacemaker implants, while a separate 2025 follow-up study reported two de novo pacemaker implantations for symptomatic bradycardia over a median of 13.1 years. However, severe outcomes persist despite these interventions. One patient with an implantable cardioverter-defibrillator (ICD) still experienced a sudden death, and three carriers in the 2025 follow-up study required hospitalization for heart failure.

Given the significant morbidity and mortality, the focus has shifted towards early risk stratification and proactive management. The critical nature of this approach is highlighted by a 2025 case report where a patient who declined a recommended ICD for high-risk of sudden cardiac death experienced a fatal cardiac arrest eight days later. Consequently, early identification through genetic testing, family screening, and risk assessment is emphasized as crucial for preventing adverse outcomes. Supporting this, studies show that children with PRKAG2 mutations exhibit echocardiographic markers of cardiac hypertrophy before clinical manifestations appear, facilitating earlier therapeutic planning. Management also extends to special populations, with successful balloon dilation for severe pulmonary valve stenosis in a one-month-old infant and recommendations for mutation carriers to avoid pregnancy due to associated complications. Future therapeutic advancements may depend on a deeper molecular understanding, as a 2022 publication noted that more detailed information on how pathogenic variants influence AMPK activity is needed to improve treatment.

Targeting the Genetic Roots of PRKAG2 Cardiomyopathy

The recent IND clearance for Atrium Therapeutics' ATR 1072 to initiate a Phase I/II clinical trial for PRKAG2 syndrome marks a pivotal moment for patients grappling with this rare and severe genetic cardiomyopathy. PRKAG2 syndrome, an autosomal dominant disorder, is characterized by a triad of cardiac hypertrophy, ventricular pre-excitation, and progressive conduction system disease, often leading to debilitating heart failure and a high risk of sudden cardiac death. Studies indicate that current management strategies are largely symptomatic, focusing on controlling arrhythmias and managing heart failure, with many patients eventually requiring pacemakers, defibrillators, or even heart transplantation.

ATR 1072 offers a fundamentally different approach: it is designed to silence the mutant PRKAG2 messenger RNA, thereby targeting the root cause of the disease rather than just its symptoms. This represents a significant strategic move, positioning Atrium Therapeutics at the forefront of developing a potentially disease-modifying therapy for a condition with profound unmet needs. Success in this early-stage trial could not only validate the company's mRNA silencing platform but also pave the way for a new therapeutic paradigm in genetic cardiomyopathies.

However, the path forward is not without its challenges. As an early-phase trial, ATR 1072 carries the inherent risks associated with novel mechanisms and unproven human efficacy. Furthermore, the clinical landscape of PRKAG2 syndrome presents unique hurdles. Research shows that the condition is often misdiagnosed as more common forms of hypertrophic cardiomyopathy, which could complicate patient identification and recruitment for the trial. The genetic and phenotypic variability of PRKAG2 mutations, leading to diverse clinical presentations, also poses a risk regarding the drug's consistent efficacy across the entire patient population. Despite these considerations, the initiation of this trial offers a beacon of hope for patients and families affected by this devastating disease, signaling a potential shift towards targeted genetic interventions.